Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.50 |
| ▸ | CCND1 | P24385 | 9/20 | 0.50 |
| ▸ | CCND2 | P30279 | 9/20 | 0.50 |
| ▸ | CCND3 | P30281 | 9/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285681 | 0.90 | FYN (0.56) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285698 | 0.89 | CDK4 (0.48) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285673 | 0.88 | FYN (0.56) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285697 | 0.88 | MAPT (0.51) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285671 | 0.86 | MEN1 (0.53) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285675 | 0.85 | EGFR (0.49) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285693 | 0.83 | CDK4 (0.50) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285670 | 0.83 | NTRK1 (0.50) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285708 | 0.83 | CDK4 (0.47) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285692 | 0.82 | CDK4 (0.46) | CDK4CCND1CCND2CCND3FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CDK4 2824/4885CCND1 4822/4885CCND2 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.